ft

FGTI-2734 is a dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor, exhibiting IC50 values of 250 nM and 520 nM for FT and GGT-1, respectively. It effectively prevents the membrane localization of KRAS, addressing the issue of KRAS resistance and inhibiting the growth of mutant KRAS patient-derived pancreatic tumors.

FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.

FT001 is a potent, selective and orally available inhibitor of BET Bromodomain with antitumor activity. FT001 inhibited the expression of MYC with the IC50 value of 0.46 μM). FT001 has potent antiproliferative effects against MV-4-11 and demonstrates significant MYC mRNA suppression both in vitro and in vivo.

FT827 is a covalent inhibitor of selective ubiquitin-specific protease 7 (USP7) (Ki=4.2 µM, Kd=7.8 µM) targeting the catalytic center of the autoinhibitory apolipoprotein form of USP7 for cancer research.

FT113 is a novel potent inhibitor of fatty acid synthase (fasn, IC50 : 213 nM),and exhibits anti-cancer activity

FT-1518 is an orally available, selective and potent mTORC1 and mTORC2 inhibitor with anticancer and antitumor activity for cancer research.

FT895 is a selective and potent HDAC11 inhibitor with antifungal and antitumor activity, inhibiting HDAC11 expression and limiting EV71 replication in vitro (in vitro).

FT671 is a non-covalent, selective USP7 inhibitor (IC50=52 nM) that binds to the catalytic domain of USP7 (Kd=7.8 µM). It disrupts the stability of USP7 substrates including MDM2, elevates p53, induces p21, and inhibits tumor growth in mice.

FT206 is a carboxamide inhibitor of ubiquitin-specific protease[1].

Notoginsenoside Ft1 is a saponin originally isolated from P. notoginseng with diverse biological activities

FT709 is a selective USP9X deubiquitinating enzyme inhibitor (IC50=82 nM) that reduces Makorin and ZNF598 levels, impairing ribosomal quality control pathways.

FT385 is a novel USP30 inhibitor, recapitulating genetic loss of USP30 and setting the trigger for PINK1-PARKIN amplification of mitochondrial ubiquitylation.

FT-1101 is an orally bioavailable, potent and selective BET inhibitor. FT-1101 binds to the acetylated lysine recognition motifs in the bromodomain sites of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.

FT011, a direct anti-fibrotic agent,attenuates cardiac remodelling and dysfunction in experimental diabetic cardiomyopathy.

FTI-2148 diTFA, a dual inhibitor targeting both farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1), functions as a RAS C-terminal mimetic. It exhibits potent inhibitory capabilities with IC50 values of 1.4 nM for FT-1 and 1.7 μM for GGT-1, respectively.

FTI-2148 is an inhibitor of RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) (IC50s: 1.4 nM and 1.7 μM, respectively).

(R)-FT671 is the R-isomer of FT671, a potent, non-covalent, and selective inhibitor of USP7 with an IC50 of 52 nM.

FT-FAPI-12_9 (TFA) serves as an FAP ligand, utilized in synthesizing the FAP-targeted radiotracer FAPI-46.

FT-1101 is an oral bioavailable, effective and selective BET inhibitor.

FT3967385 is a newly developed compound that functions as a USP30 inhibitor, emulating the genetic deficiency of USP30. This inhibition serves as a catalyst for the amplification of mitochondrial ubiquitylation through the PINK1-PARKIN pathway.

(R)-FT709 is an active compound utilized in cancer research [1].

Notoginsenoside Ft1 (Standard) is a reference standard for research and analysis in studies involving Notoginsenoside Ft1. Notoginsenoside Ft1 is a saponin originally isolated from P. notoginseng with diverse biological activities

Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.

(Rac)-Etavopivat ((Rac)-FT-4202), an isomer of Etavopivat, is an orally active erythrocyte pyruvate kinase-R (PKR) activator used in sickle cell disease and haemoglobinopathy research [1].